The Medical Letter on Drugs and Therapeutics
Sodium Zirconium Cyclosilicate (Lokelma) for Hyperkalemia
The full article is available to subscribers Subscriber Login   

The FDA has approved sodium zirconium cyclosilicate (Lokelma – AstraZeneca), an oral potassium binder that exchanges hydrogen and sodium for potassium in the gastrointestinal (GI) lumen, for treatment of non-life-threatening hyperkalemia in adults. Sodium zirconium cyclosilicate (SZC) is the third drug to be approved for this indication; sodium polystyrene sulfonate and patiromer (Veltassa)1 were approved earlier.

HYPERKALEMIA — Risk factors for hyperkalemia include renal disease, diabetes, and heart failure. The risk is increased with use of drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) such as angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), direct renin inhibitors, and aldosterone antagonists. Dosage reduction or discontinuation of RAAS inhibitors because of hyperkalemia is sometimes required. Some ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Sodium Zirconium Cyclosilicate (Lokelma) for Hyperkalemia
Article code: 1561c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian